Lisata Therapeutics

433 articles about Lisata Therapeutics

• Caladrius Biosciences Awarded Approximately $2 Million NIH Grant To Support Clinical Study Of CLBS14 In Patients With Coronary Microvascular Dysfunction

  10/2/2017

• Caladrius Biosciences Announces Enrollment Of The 70th Subject In The Phase II T-Rex Clinical Trial Of CLBS03 For Type 1 Diabetes

  9/5/2017

• Caladrius Biosciences Reports 2017 Second Quarter Results

  8/11/2017

• Caladrius Biosciences To Host 2017 Second Quarter Results Conference Call On August 10, 2017 At 4:30 P.M. Eastern Time

  8/3/2017

• Caladrius Biosciences Announces That 50% Of Subjects Have Been Treated In The Phase II Clinical Trial Of CLBS03 For Type 1 Diabetes

  7/19/2017

• Caladrius Biosciences Joins Russell Microcap Index

  6/26/2017

• Caladrius Biosciences Closes The Sale Of Its Remaining Interest In PCT To Hitachi Chemical Co., Ltd. For $75 Million

  5/19/2017

• Caladrius Biosciences Announces 2017 First Quarter Financial Results

  5/16/2017

• Caladrius Biosciences To Hold 2017 Annual Stockholder Meeting On May 16

  4/11/2017

• Caladrius Biosciences Announces Addition Of Four Clinical Sites, Including Joslin Diabetes Center, For The Ongoing Phase II Study Of CLBS03 In T1D

  4/3/2017

• Hitachi Chemical Co., Ltd. Signs Agreement To Purchase From Caladrius Biosciences The Remaining 80.1% Interest In PCT For $75 Million

  3/17/2017

• Hitachi Chemical Co., Ltd. Signs Agreement To Purchase From Caladrius Biosciences The Remaining 80.1% Interest In PCT For $75 Million

  3/17/2017

• Caladrius Biosciences Announces 2016 Fourth Quarter And Full Year Financial Results

  3/17/2017

• Caladrius Biosciences To Host 2016 Fourth Quarter And Full Year Financial Results Conference Call On March 17, 2017 At 8:30 Am Eastern Time

  3/13/2017

• Caladrius Biosciences Awarded $12.2 Million Grant From CIRM In Support Of Phase II Clinical Trial Of CLBS03 To Treat Type 1 Diabetes

  2/24/2017

• Caladrius Biosciences Release: Biotech Announces Addition Of Three Clinical Sites, Including UCSF, For The Ongoing Phase 2 Study Of CLBS03 In T1D

  1/25/2017

• Caladrius Biosciences Updates Status Of Receipt Of Funds For A Portion Of Previously Announced Private Placement

  1/9/2017

• Caladrius Biosciences To Host 2016 Third Quarter Financial Results Conference Call On November 7 At 5:00 PM Eastern Time

  11/3/2016

• Caladrius Biosciences Appoints Gregory R. Brown, MD, To Its Board Of Directors

  10/12/2016

• Caladrius Biosciences To Present At Upcoming October Conferences

  10/4/2016